Surrozen, Inc. — Form 8-K Summary
Report date: August 11, 2022
Reporting period: Quarter ended June 30, 2022
Business Context and Filing Purpose
Surrozen, Inc., a Delaware biotechnology company, filed this Current Report under Item 2.02 to announce the issuance of a press release regarding its financial results for the quarter ended June 30, 2022. The company’s common stock and redeemable warrants trade on the Nasdaq Capital Market under the symbols SRZN and SRZNW, respectively.
Financial Results and Liquidity
The filing states that a financial-results press release was issued, but the text provided does not include the press release or specific financial statements. Accordingly, revenue, net loss or profit, operating expenses, cash flow, margins, debt, cash balances, liquidity, and other financial metrics are not clearly provided.
Changes Versus Prior Comparable Period
The provided filing text does not disclose quantitative or qualitative comparisons with the prior-year or prior-quarter period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, management outlook, risk updates, contingencies, or unusual items. Any such information may be contained in Exhibit 99.1, the referenced press release, which is not included in the supplied content.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the detailed quarterly financial results.
- Verify revenue, net loss, operating expenses, cash and cash equivalents, cash burn, and remaining liquidity.
- Review management’s discussion of clinical programs, development timelines, financing needs, and forward-looking guidance.
- Confirm any changes in debt, share count, warrant obligations, or other financing arrangements.
- Note that the Item 2.02 information, including the referenced exhibit, is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.